Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Associated Cardiotoxicity: A Recent Five-Year Pharmacovigilance Study

Background: Clinical trials frequently reported anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) associated with cardiac adverse drug events (AEs) but minimal postmarketing data. We aimed to research real-world cardiac disorders associated with ALK-TKIs based on the Food and Drug Adm...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yihan, Chen, Chen, Rong, Chencheng, He, Xucheng, Chen, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968911/
https://www.ncbi.nlm.nih.gov/pubmed/35370632
http://dx.doi.org/10.3389/fphar.2022.858279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968911/
https://www.ncbi.nlm.nih.gov/pubmed/35370632
http://dx.doi.org/10.3389/fphar.2022.858279

Ejemplares similares